The consequential distinction is that PPHM has revealed nothing of even a general nature about any proprietary technology it might have that would purportedly enable it to be a serious player in FoB’s. MNTA’s proprietary technology, on the other hand, has been published in peer-reviewed journals and has passed muster with the FDA.
You’re really out in left field, IMO, to mention PPHM and MNTA in the same sentence when you are talking about FoB’s and the characterization of complex compounds.
Market Data 
Markets 
AI
